Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast CancerHeikki Joensuu, Henrik Lindman, Judith Fraser et al.|JAMA Oncology|2018Cited by 149
Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX TrialHeikki Joensuu, Henrik Lindman, R. Kokko et al.|Journal of Clinical Oncology|2011Cited by 118
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast CancerHeikki Joensuu, Henrik Lindman, Pirkko‐Liisa Kellokumpu‐Lehtinen et al.|JAMA Oncology|2017Cited by 95
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trialHeikki Joensuu, Henrik Lindman, Pirkko‐Liisa Kellokumpu‐Lehtinen et al.|The Lancet Oncology|2009Cited by 65
Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX)Heikki Joensuu, Henrik Lindman, Pirkko‐Liisa Kellokumpu‐Lehtinen et al.|Acta Oncologica|2013Cited by 24